Bayer Menopause Drug Lands FDA Approval, Bringing Competition to an Astellas Product
A Bayer drug that hits two central nervous system targets to treat moderate-to-severe menopause symptoms has FDA approval, introducing a new non-hormonal therapeutic option that may have an advantage over an Astellas Pharma product that has a two-year head start in this market. The Bayer drug, elinzanetant, is a small molecule formulated as a soft…